ArticleCell death discovery2026
Humic substances enhance the anti-cancer efficacy of standard therapies.
Article in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The green oncology paradigm emphasizes the use of natural products in cancer treatment to protect the environment while reducing the adverse effects associated with conventional therapies. In this context, humic substances (HSs), derived from the degradation of waste biomass, have emerged as promising candidates due to their diverse bioactive properties. Beyond their well-known antioxidant and antimicrobial effects, this study demonstrates the antitumor potential of HSs extracted from olive (HS-OL) and artichoke (HS-CYN). Our results reveal that HS-OL and HS-CYN significantly induce DNA damage by triggering apoptosis and reducing cell viability in cancer cells across various histotypes. When used in combination with standard therapies, these HSs enhance therapeutic efficacy, enabling the use of lower doses of chemotherapeutic agents while maintaining their effectiveness. The introduction of HSs into cancer treatment represents a sustainable and innovative approach that not only reduces the ecological footprint but also minimizes the side effects associated with traditional anticancer drugs, offering a dual benefit for both patients and the environment.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.